You have free access to this contentAddition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies.

Autor: Prebet, Thomas, Delaunay, Jacques, Wattel, Eric, Braun, Thorsten, Cony‐Makhoul, Pascale, Dimicoli, Sophie, Wickenhauser, Stephan, Lejeune, Julie, Chevret, Sylvie, Chermat, Fatiha, Fenaux, Pierre, Vey, Norbert
Předmět:
Zdroj: British Journal of Haematology; Mar2018, Vol. 180 Issue 5, p735-737, 3p
Abstrakt: The article looks at a study regarding the addition of suberoylanilide hydroxamic acid to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure. It mentions DNA methylation and histone deacetylation (HDAC) are synergistic in terms of gene silencing and the combination of inhibitors. It also mentions toxicity and efficacy of new drugs in combination with hypomethylating agents (HMAs).
Databáze: Complementary Index